Drug
SAT-3247
SAT-3247 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Completed1
Enrolling by invitation1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
completed133%
enrolling_by_invitation133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189
enrolling_by_invitationphase_2
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
NCT06867107
completedearly_phase_1
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
NCT06565208
Clinical Trials (3)
Showing 3 of 3 trials
NCT07287189Phase 2
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT06867107Phase 2
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
NCT06565208Early Phase 1
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3